Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects

The Journal of Pharmacy and Pharmacology
Naveen AhujaBhupinder Singh

Abstract

Rofecoxib (MK-966) is a new generation non-steroidal anti-inflammatory agent (NSAID) that exhibits promising anti-inflammatory, analgesic and antipyretic activity. It selectively inhibits cyclooxygenase (COX)-2 isoenzyme in a dose-dependent manner in man. No significant inhibition of COX-1 is observed with rofecoxib up to doses of 1000 mg. The pharmacokinetics of rofecoxib has been found to be complex and variable. Mean oral bioavailability after single dose of rofecoxib (12.5, 25 or 50 mg) is 93% with t(max) varying widely between 2 and 9 h. It is highly plasma-protein bound and is metabolized primarily by cytosolic reductases to inactive metabolites. Rofecoxib is eliminated predominantly by hepatic metabolism with a terminal half-life of approximately 17 h during steady state. Various experimental models and clinical studies have demonstrated rofecoxib to be superior, or at least equivalent, in anti-inflammatory, analgesic and antipyretic efficacy to comparator nonselective NSAIDs in osteoarthritis, rheumatoid arthritis and other pain models. Emerging evidence suggests that rofecoxib may also find potential use as supportive therapy in various pathophysiologic conditions like Alzheimer's disease, and in various malignant tumo...Continue Reading

References

Apr 1, 1975·The Journal of Clinical Investigation·J C FrölichJ A Oates
May 8, 1991·Biochimica Et Biophysica Acta·D L DeWitt
Oct 1, 1991·Annals of the Rheumatic Diseases·I E Buchan, H A Bird
Jun 1, 1995·The Annals of Pharmacotherapy·R L Slaughter, D J Edwards
Jan 1, 1995·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·J R Vane, R M Botting
Mar 1, 1995·Current Opinion in Rheumatology·M Dougados
Dec 1, 1994·Clinical Pharmacokinetics·J R Brouwers, P A de Smet
Dec 1, 1994·The Journal of Clinical Investigation·R C HarrisM D Breyer
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J A MitchellJ R Vane
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·W E KaufmannP Isakson
Jan 1, 1996·Advances in Immunology·W L Smith, D L Dewitt
Nov 1, 1996·Nature Structural Biology·C LuongM F Browner
Dec 27, 1996·The Journal of Biological Chemistry·W L SmithD L DeWitt
Feb 1, 1997·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·E WongD Riendeau
Nov 14, 1997·Kidney International·B L Jensen, A Kurtz
Jan 1, 1997·Journal of Clinical Gastroenterology·H SawaokaM Hori
Feb 3, 1999·Lancet·C J Hawkey
Apr 9, 1999·The Journal of Clinical Investigation·H F ChengR C Harris
Jul 3, 1999·Clinical Pharmacology and Therapeutics·J I SchwartzB J Gertz
Jul 21, 1999·Journal of the National Cancer Institute·J Ziegler
Sep 14, 1999·The American Journal of Physiology·N R FerreriJ C McGiff
Sep 24, 1999·The Annals of Pharmacotherapy·B Kaplan-Machlis, B S Klostermeyer
Sep 24, 1999·Drugs·L J Scott, H M Lamb
Dec 2, 1999·JAMA : the Journal of the American Medical Association·M J LangmanT J Simon

❮ Previous
Next ❯

Citations

Mar 27, 2007·Pharmaceutical Research·Chong-Hui GuRonald L Smith
Aug 18, 2004·Current Opinion in Rheumatology·Burkhard Hinz, Kay Brune
Jul 1, 2008·Indian Journal of Pharmaceutical Sciences·Madhur Kulkarni, Mangal Nagarsenker
Dec 27, 2007·Nuclear Medicine and Biology·Erik F J de VriesAren van Waarde
Nov 10, 2004·Oral Diseases·J V BagánC Scully
Jul 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Ashish DhirShrinivas K Kulkarni
Sep 12, 2006·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Naveen AhujaBhupinder Singh
Sep 1, 2005·Expert Review of Clinical Immunology·Werner Kiefer, Gerd Dannhardt
Sep 30, 2020·Journal of Biomolecular Structure & Dynamics·Loubna TaidiMohammed Reda Britel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

© 2021 Meta ULC. All rights reserved